Two Sigma Advisers
EBS icon

Two Sigma Advisers’s Emergent Biosolutions EBS Stock Holding History

Two Sigma Advisers’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-45,400
Closed -$561K – 649
2025
Q4 		$561K Buy
45,400
+2,200
+5% +$23.6K ﹤0.01% 1732
2025
Q3 		$381K Sell
43,200
-240,500
-85% -$1.87M ﹤0.01% 1885
2025
Q2 		$1.81M Sell
283,700
-129,000
-31% -$738K ﹤0.01% 1175
2025
Q1 		$2.01M Sell
412,700
-243,800
-37% -$2.02M ﹤0.01% 1157
2024
Q4 		$6.28M Buy
656,500
+81,000
+14% +$743K 0.01% 632
2024
Q3 		$4.81M Buy
575,500
+100
+0% +$909 0.01% 713
2024
Q2 		$3.92M Sell
575,400
-498,400
-46% -$2.14M 0.01% 873
2024
Q1 		$2.72M Sell
1,073,800
-13,900
-1% -$31.3K 0.01% 1060
2023
Q4 		$2.61M Buy
1,087,700
+20,400
+2% +$47.9K 0.01% 1131
2023
Q3 		$3.63M Buy
1,067,300
+350,400
+49% +$1.94M 0.01% 895
2023
Q2 		$5.27M Buy
716,900
+227,800
+47% +$2.11M 0.01% 753
2023
Q1 		$5.07M Buy
489,100
+256,200
+110% +$3.1M 0.01% 803
2022
Q4 		$2.75M Sell
232,900
-3,700
-2% -$57.3K 0.01% 1064
2022
Q3 		$4.97M Sell
236,600
-6,300
-3% -$175K 0.01% 737
2022
Q2 		$7.54M Sell
242,900
-24,100
-9% -$823K 0.02% 602
2022
Q1 		$11M Buy
267,000
+123,200
+86% +$5.43M 0.03% 483
2021
Q4 		$6.25M Buy
143,800
+138,400
+2,563% +$6.26M 0.02% 677
2021
Q3 		$270K Sell
5,400
-248,600
-98% -$15.1M ﹤0.01% 2155
2021
Q2 		$16M Buy
+254,000
New +$16.3M 0.04% 389
2020
Q4 		– Sell
-153,700
Closed -$15.9M – 2440
2020
Q3 		$15.9M Buy
+153,700
New +$16.6M 0.05% 380
2019
Q3 		– Sell
-6,500
Closed -$314K – 2263
2019
Q2 		$314K Buy
+6,500
New +$312K ﹤0.01% 1998
2019
Q1 		– Sell
-6,300
Closed -$373K – 2334
2018
Q4 		$373K Sell
6,300
-10,300
-62% -$664K ﹤0.01% 1885
2018
Q3 		$1.09M Sell
16,600
-26,590
-62% -$1.55M ﹤0.01% 1475
2018
Q2 		$2.18M Sell
43,190
-11,300
-21% -$589K 0.01% 1257
2018
Q1 		$2.87M Sell
54,490
-10,000
-16% -$498K 0.01% 1074
2017
Q4 		$3M Buy
64,490
+9,300
+17% +$391K 0.01% 1058
2017
Q3 		$2.23M Sell
55,190
-19,600
-26% -$709K 0.01% 1143
2017
Q2 		$2.54M Sell
74,790
-21,200
-22% -$654K 0.01% 1087
2017
Q1 		$2.79M Sell
95,990
-38,900
-29% -$1.18M 0.01% 1095
2016
Q4 		$4.43M Sell
134,890
-25,200
-16% -$756K 0.02% 789
2016
Q3 		$5.05M Buy
160,090
+15,700
+11% +$456K 0.02% 643
2016
Q2 		$4.06M Buy
144,390
+19,000
+15% +$745K 0.02% 616
2016
Q1 		$4.56M Sell
125,390
-12,700
-9% -$449K 0.03% 529
2015
Q4 		$5.53M Buy
138,090
+9,600
+7% +$335K 0.03% 420
2015
Q3 		$3.69M Sell
128,490
-9,900
-7% -$326K 0.02% 553
2015
Q2 		$4.56M Sell
138,390
-3,100
-2% -$96.1K 0.03% 511
2015
Q1 		$4.07M Buy
141,490
+37,200
+36% +$1.07M 0.03% 544
2014
Q4 		$2.84M Buy
104,290
+3,900
+4% +$92.9K 0.02% 685
2014
Q3 		$2.14M Sell
100,390
-8,500
-8% -$195K 0.02% 790
2014
Q2 		$2.45M Sell
108,890
-89,600
-45% -$2.09M 0.02% 730
2014
Q1 		$5.02M Buy
198,490
+124,600
+169% +$3.15M 0.05% 422
2013
Q4 		$1.7M Buy
73,890
+11,400
+18% +$238K 0.02% 827
2013
Q3 		$1.19M Buy
62,490
+9,150
+17% +$163K 0.01% 874
2013
Q2 		$769K Buy
+53,340
New +$772K 0.01% 1016

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Advisers's EBS Position: Q1 2026 in Review

Two Sigma Advisers sold out of Emergent Biosolutions (EBS) in Q1 2026, closing a stake of 45,400 shares — an estimated $561K sold.

Two Sigma Advisers first reported a position in EBS in Q2 2013 and held it in 44 quarters. The position peaked at $16M in Q2 2021. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.

  • Two Sigma Advisers reported no remaining Emergent Biosolutions position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 45,400 Emergent Biosolutions shares in Q1 2026, an estimated $561K.
  • Two Sigma Advisers first reported a position in Emergent Biosolutions in Q2 2013 and held it in 44 quarters.
  • Two Sigma Advisers's Emergent Biosolutions position peaked at $16M in Q2 2021.
  • 190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.